Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1562517 | 0.95 | AR (0.42) | ARFFAR1ALDH1A1MAPTHPGD | |
| SCHEMBL2882411 | 0.83 | FFAR1 (0.40) | FFAR1PPARG | |
| SCHEMBL8404390 | 0.82 | AR (0.51) | ARFFAR1NR1I2SMARCA2SMARCA4 | |
| SCHEMBL2333492 | 0.82 | ROCK2 (0.44) | FFAR1 | |
| SCHEMBL2326646 | 0.82 | ROCK2 (0.44) | FFAR1 | |
| SCHEMBL2332861 | 0.82 | ROCK2 (0.44) | FFAR1 | |
| SCHEMBL2879248 | 0.80 | HRH3 (0.39) | FFAR1 | |
| SCHEMBL9892986 | 0.79 | FFAR1 (0.55) | ARFFAR1PPARGPSEN1PSEN2 | |
| SCHEMBL8156048 | 0.79 | FFAR1 (0.45) | ARFFAR1NR1I2SMARCA2SMARCA4 | |
| SCHEMBL25956608 | 0.77 | MAPT (0.49) | ARFFAR1NR1I2SMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509600-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-06-15 | — | — | US | disclosed |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2013-02-07 | — | — | US | disclosed |
| EP-2509600-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | Agios Pharmaceuticals, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011072174-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | AR 1859/4885FFAR1 4515/4885NR1I2 4347/4885 |
| US-20130035329-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | AR 1859/4885FFAR1 4515/4885NR1I2 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.